Detalles de la búsqueda
1.
Supportive care in cancer-a MASCC perspective.
Support Care Cancer
; 28(8): 3467-3475, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32342221
2.
Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada.
Support Care Cancer
; 28(10): 5031-5036, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32601854
3.
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Breast Cancer Res Treat
; 168(1): 159-168, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177603
4.
Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice.
Support Care Cancer
; 26(Suppl 1): 29-33, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29556813
5.
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
Support Care Cancer
; 26(8): 2519-2549, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29796708
6.
Age-Related Patterns in Cancer Pain and Its Psychosocial Impact: Investigating the Role of Variability in Physical and Mental Health Quality of Life.
Pain Med
; 19(4): 658-676, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28340045
7.
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 289-294, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27510316
8.
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
Support Care Cancer
; 25(1): 271-275, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27501965
9.
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
Support Care Cancer
; 25(1): 277-288, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27443154
10.
The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options.
Support Care Cancer
; 25(6): 1915-1922, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28155019
11.
Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
Support Care Cancer
; 24(5): 1941-1954, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26476625
12.
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Oncologist
; 20(4): 450-8, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25795636
13.
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Breast Cancer Res Treat
; 146(1): 153-62, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24924416
14.
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
Support Care Cancer
; 22(6): 1685-97, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24590374
15.
Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-CME information.
Support Care Cancer
; 26(Suppl 1): 1-2, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29556807
16.
Management of highly emetogenic chemotherapy.
Curr Opin Oncol
; 24(4): 371-5, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22476193
17.
Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 295-296, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27624467
18.
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Support Care Cancer
; 19(6): 807-13, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20461438
19.
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Support Care Cancer
; 19(9): 1297-302, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20623144
20.
Acute emesis: moderately emetogenic chemotherapy.
Support Care Cancer
; 19 Suppl 1: S15-23, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20680356